Onyx shares rise on reports it is exploring options

11/28/2011 | Bloomberg

Onyx Pharmaceuticals' stock price rose as sources said the biopharmaceutical firm is reviewing strategic alternatives, including the possibility of a sale of the company. Last month, Onyx ended a dispute with Bayer regarding cancer drug candidate regorafenib, and the companies amended a partnership for kidney cancer medicine Nexavar.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA